Table 2.
Patient demographics, study drug, level of self-reported side effects, and mean System Usability Scale (SUS) score for each tech group.
| Characteristics | Tech group 1 (n=68): no intervention |
Tech group 2 (n=26): 1-2 simple reminders | Tech group 3 (n=24): technical support once | Tech group 4 (n=10): support on multiple occasions | Tech group 5 (n=6): unable to use | |
| Proportion of the total sample (95% CI) | 0.51 (0.39-0.62) | 0.19 (0.12-0.30) | 0.18 (0.10-0.27) | 0.07 (0.03-0.15) | 0.05 (0.01-0.11) | |
| Sex, n (%) | ||||||
|
|
Male | 29 (43) | 10 (38) | 12 (50) | 6 (60) | 4 (67) |
|
|
Female | 39 (57) | 16 (62) | 12 (50) | 4 (40) | 2 (33) |
| Age (years), mean (SD) | 61 (9.82) | 58 (9.76) | 64 (9.92) | 62 (7.69) | 71 (5.37) | |
| LOSa (days), mean (SD) | 2.1 (0.66) | 2.5 (0.76) | 2.1 (0.58) | 2.3 (0.95) | 2.5 (0.84) | |
| Study drug in original trial, n (%) | ||||||
|
|
Oxycodone depot | 23 (34) | 12 (46) | 6 (25) | 3 (30) | 2 (33) |
|
|
Tapentadol depot | 24 (35) | 8 (31) | 10 (42) | 3 (30) | 0 (0) |
|
|
Placebo | 21 (31) | 6 (23) | 8 (33) | 4 (40) | 4 (67) |
| SUSb form completed, n (%) | 61 (90) | 25 (96) | 21 (88) | 9 (90) | 3 (50) | |
| SUS score, mean | 91.8 | 92.9 | 85.2 | 84.4 | 65.8 | |
| Pain (at rest), meanc | 2.17 | 2.35 | 2.09 | 3.26 | 1.21 | |
| Constipation, meanc | 0.66 | 0.47 | 0.42 | 0.59 | 0.93 | |
| Dizziness, meanc | 0.95 | 1.13 | 0.88 | 2.29 | 0.57 | |
| Headache, meanc | 0.42 | 0.76 | 0.59 | 0.90 | 0.14 | |
| Nausea, meanc | 0.88 | 1.08 | 0.99 | 1.79 | 0.76 | |
| Sedation, meanc | 2.03 | 2.21 | 2.16 | 3.26 | 1.21 | |
| Sleep quality, meanc | 2.97 | 3.4 | 3.49 | 4.53 | 1.98 | |
| Amount of rescue drug (oxycodone 5 mg tablet), mean value per 24 hours | 1.59 | 2.3 | 1.79 | 3.2 | 1.02 | |
| Used personal tablet, n | 30 (44) | 9 (35) | 7 (29) | 2 (20) | 1 (17) | |
| Used borrowed tablet, n (%) | 38 (56) | 17 (65) | 17 (71) | 8 (80) | 5 (83) | |
aLOS: length of hospital stay.
bSUS: System Usability Scale.
cMeasured on a 0-10 numeric rating scale (0=best, 10=worst).